fashion -WSS

fashion

author：focus 2025-09-29 20:52:55 - browse：1435

FDA-Blood Sugar Monitor — The FDA has approved a device from Abbott that continuously monitors diabetics’ blood sugar levels without requiring backup finger prick tests. Abbott Laboratories via AP

U.S. regulators have approved the first continuous blood sugar monitor for diabetics that doesn’t need backup finger prick tests.

Current models require users to test a drop of blood twice daily to calibrate, or adjust, the monitor.

The pain of finger sticks and the cost of testing supplies discourage many people from keeping close tabs on their blood sugar, which is needed to manage insulin use and adjust what they eat.

Abbott’s new FreeStyle Libre Flash Glucose Monitoring System, approved Wednesday by the Food and Drug Administration, uses a small sensor attached to the upper arm. Patients wave a reader device over it to see the current blood sugar level and changes over the past eight hours.

Most of the 30 million Americans with diabetes use standard glucose meters, which require multiple finger pricks each day and only show current sugar level. More-accurate continuous glucose monitoring devices are used by about 345,000 Americans.

Newsletters

Sign up for Morning Rounds

Your daily dose of news in health and medicine.

Please enter a valid email address. Privacy Policy

But most don’t do the finger pricks to calibrate them and may get inaccurate readings, said Dr. Timothy Bailey, who helped test FreeStyle Libre.

“We’re able to lower blood sugar safely” with this technology, said Bailey, director of the Advanced Metabolic Care and Research Institute in California. He receives consulting fees from various diabetes device makers.

Too-high blood sugar levels can damage organs and lead to heart attacks, strokes, blindness and amputations. Very low blood sugar can cause seizures, confusion and loss of consciousness.

Abbott’s device was approved for adults with type 1 or type 2 diabetes and should be available in pharmacies within months. The company, based near Chicago, did not disclose the price of the reader or the sensors.

Abbott’s system can’t be used with an insulin pump, a device worn against the skin that allows users to inject insulin as needed, but the company is planning improvements to eventually enable that.

Rival Medtronic this spring launched a device in which the insulin pump automatically responds to blood sugar changes recorded by the sensor and either withholds or injects insulin as needed.

— Linda A. Johnson

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： The system is set up to fail children with medical complexity

hotspot

WSS

Exact Sciences stock tumbles despite strong cancer detection sales

Statins may not be needed by millions of people, study suggests

Getting Alzheimer's drug Leqembi to patients can be a challenge

Melinda French Gates resigns from Gates Foundation

NIH tests clinical research in primary care with $30 million program

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

hotspot

fashion

Sign up for Morning Rounds

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Deposition: Sackler embraced plan to conceal OxyContin’s strength

In age of alternative facts, a scholarly course on calling out crap

Health care needs a new profession: neuroimaging counseling

The cancer drug shortage isn’t new — and neither are the solutions

Bird flu outbreak in cows is latest avian flu curveball

Jerome Adams on the need for new antivirals for Covid

Why does health care cost so much? A reading guide

Peter Hotez and the public health issue of online harassment

5 takeaways from STAT's examination of Zynex Medical

entertainment

Readers discuss the intersection of pregnancy and addiction

Exact Sciences stock tumbles despite strong cancer detection sales

The system is set up to fail children with medical complexity

H5N1 bird flu virus started spreading in cows in Texas in December

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Lilly's Alzheimer's drug donanemab backed by FDA advisers

hotspot

leisure time

focus

hotspot